Development of effective addiction treatments has been difficult, likely in part because addiction treatment re- search has generally targeted the end symptom of drug use, and there are many possible etiological pathways to drug use. The goal of this award is to support the training and career development of Dr. Margaret Wardle, in the context of a research program that will instead target underlying neurobehavioral dysfunctions to improve addiction treatment outcomes. Dr. Wardle's long-term career goal is to become an independent scientist using a neuroscience-based approach to treatment development for addiction. The proposed training builds on Dr. Wardle's prior experience with drug effects in healthy adults by increasing her expertise in: 1. Clinical re- search, including behavioral and medication treatments for addiction; 2. Functional Magnetic Resonance Imaging to directly measure underlying neural processes; 3. Advanced Bayesian statistical methods to increase in- formation gained from smaller trials. This training will position Dr. Wardle as an independent scientist at the cutting edge of addiction treatment development. The complementary research program uses a proof-of- concept design, targeting one specific neurobehavioral dysfunction, anhedonia, i.e. lack of interest or pleasure in non-drug rewards, in Cocaine Use Disorder (CUD), and specifically in contingency management (CM), a validated CUD treatment in which individuals receive non-drug rewards for abstaining. Several lines of evidence suggest that anhedonia negatively affects CM, that dopaminergic (DAergic) drugs improve CM outcomes, and that this improvement may be mediated by reduced anhedonia. Dr. Wardle's own preliminary data has established that anhedonia predicts worse outcomes in CM for CUD, and that DAergic drugs can enhance responsiveness to rewards. The current grant will integrate and expand on these findings by fully testing the hypothesis that anhedonia is a key neurobehavioral dysfunction in CUD that affects CM outcomes, and that DAergic drugs enhance CM by reducing anhedonia. This will be accomplished by: 1. Testing the relationship of anhedonia to CUD severity at baseline, 2. Testing whether baseline anhedonia predicts outcomes in an intensive 4 week CM treatment. 3. Testing the role of anhedonia in DAergic enhancement of CM, by examining the effects of CM combined with a DAergic stimulant against CM alone and a DAergic stimulant alone, and measuring effects on anhedonia and clinical outcomes. This study will use a neuroscience-based approach to anhedonia that measures multiple possible underlying deficits in reward functioning across subjective, behavioral, psychophysiological and neural levels. This work will: 1. Contribute to personalized medicine for CUD by establishing a key moderator of a validated treatment 2. Demonstrate the value of targeting neurobehavioral processes in addiction treatment 3. Provide Dr. Wardle with training in clinical research, imaging, and Bayesian statistics needed to apply this approach to accelerate the development of addiction treatments.

Public Health Relevance

Cocaine Use Disorder (CUD) is a devastating public health problem that has been relatively resistant to standard treatment development approaches. The current application upends symptom-focused approaches to treatment development, and starts instead from the known neural pathology of CUD to identify and directly target an underlying neurobehavioral dysfunction likely to contribute to poor outcomes in CUD treatment. This study has the potential to advance the NIH's mission to prevent disease and protect and improve public health by i) personalizing treatment for CUD by identifying an underlying disease process that contributes to differences in treatment outcomes, and ii) training an early career scientist who will then be able to apply this same disease-process focused approach to advance addiction treatment development more broadly.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DA040006-03
Application #
9477621
Study Section
Interventions to Prevent and Treat Addictions Study Section (IPTA)
Program Officer
Lao, Guifang
Project Start
2016-05-01
Project End
2018-07-13
Budget Start
2018-05-01
Budget End
2018-07-13
Support Year
3
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Psychiatry
Type
Schools of Medicine
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77030
Wardle, Margaret C; Lopez-Gamundi, Paula; LaVoy, Emily C (2018) Effects of an acute bout of physical exercise on reward functioning in healthy adults. Physiol Behav 194:552-559
Wardle, Margaret C; Vincent, Jessica N; Suchting, Robert et al. (2017) Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder. J Subst Abuse Treat 72:32-39